Clarient (CLRT) Misses Q3 EPS by 5c; Guides Lower for FY Revenues - Below Consensus
More News related to CLRT
- Clarient to Present at Upcoming Healthcare Investor Conferences in New York City
- Cardiac Science Appoints Healthcare Executive Ronald A. Andrews, Jr. to Board of Directors
- Morning Movers 11/04: MPAC, ABK, GNVC, RHB, IRE, PACR Higher; STEC, CLRT, VG, TRLG, ANSW Lower
- After-Hours Movers 11/03: QLTY, PACR, BGCP, TESO Higher; STEC, TRLG, CLRT, CRL, MYGN Lower
- Clarient (CLRT) Misses Q3 EPS by 5c; Guides Lower for FY Revenues - Below Consensus
Clarient, Inc. (NASDAQ: CLRT) reports a Q3 loss of $0.04, 5 cents worse than the analyst estimate of $0.01. Revenue for the quarter was $21.4 million, which compares to the estimate of $25.53 million.
"Taking into account these new estimates, we are now revising our revenue guidance for 2009 to $90 million to $94 million from the previous range of $96 million to $101 million. Even at the low end of the range, this will represent a year-over-year growth rate of greater than 22 percent from our 2008 revenues of $73.7 million." (Consensus is $98.46M)
Related Categories
EarningsGuidance
Stocks Mentioned
-0.01Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
